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Upregulation of Ca2+-permeable AMPA receptors (CP-AMPARs) in the dorsal horn
(DH) neurons of the spinal cord has been causally linked to the maintenance of
persistent inflammatory pain. Therefore, inhibition of CP-AMPARs could potentially
alleviate an, otherwise, poorly treatable chronic pain. However, a loss of CP-
AMPARs could produce considerable side effects because of the crucial role of
CP-AMPARs in synaptic plasticity. Here we have tested whether the inhibition of
spinal CP-AMPARs with dicationic compounds, the open-channel antagonists acting
in an activity-dependent manner, can relieve inflammatory pain without adverse
effects being developed. Dicationic compounds, N1-(1-phenylcyclohexyl)pentane-
1,5-diaminium bromide (IEM-1925) and 1-trimethylammonio-5-1-adamantane-methyl-
ammoniopentane dibromide (IEM-1460) were applied intrathecally (i.t.) as a
post-treatment for inflammatory pain in the model of complete Freund’s adjuvant
(CFA)-induced long-lasting peripheral inflammation. The capability of dicationic
compounds to ameliorate inflammatory pain was tested in rats in vivo using the
Hargreaves, the von Frey and the open-field tests. Treatment with IEM-1460 or
IEM-1925 resulted in profound alleviation of inflammatory pain. The pain relief appeared
shortly after compound administration. The effects were concentration-dependent,
displaying a high potency of dicationic compounds for alleviation of inflammatory
hyperalgesia in the micromolar range, for both acute and long-lasting responses.
The period of pain maintenance was shortened following treatment. Treatment with
IEM-1460 or IEM-1925 changed neither thermal and mechanical basal sensitivities nor
animal locomotion, suggesting that inhibition of CP-AMPARs with dicationic compounds
does not give rise to detectable side effects. Thus, the ability of dicationic compounds
to alleviate persistent inflammatory pain may provide new routes in the treatment of
chronic pain.
Keywords: dicationic compounds, Ca2+-permeable AMPA receptors, the activity-dependent inhibition, dorsal
horn, persistent inflammatory pain, antinociception
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INTRODUCTION
Persistent or chronic pain is a prominent healthcare problem
worldwide, which is defined by the International Association for
the Study of Pain (IASP) as a disease on its own, without apparent
biological value that needs to be utterly eliminated after its
appearance. Despite considerable efforts, chronic pain remains
poorly treatable, attended with side effects and adaptation to a
treatment, representing a growing clinical problem that requires
new routes based on a mechanism-targeted therapy.
It is known that upregulation of AMPA receptors (AMPARs)
in the dorsal horn (DH) neurons causes central sensitization,
a specific form of synaptic plasticity in the DH sustainable
for a long period of time (Woolf and Salter, 2000; Ji et al.,
2003). Peripheral inflammatory pain induces upregulation
of Ca2+-permeable AMPARs (CP-AMPARs) both at the
synapses (Hartmann et al., 2004; Vikman et al., 2008;
Park et al., 2009) and the extrasynaptic membranes of DH
interneurons (Park et al., 2009; Kopach et al., 2011, 2013),
two of those are causally linked to the persistent pain
maintenance (Kopach and Voitenko, 2013). Preventing the
upregulation of CP-AMPARs in DH interneurons through the
interference with molecular mechanisms of AMPAR trafficking
has been demonstrated as an effective way to alleviate
persistent inflammatory pain at the periphery (Park et al.,
2009; Kopach et al., 2013). However, inhibition of central
receptors with genetic approaches remains restricted in practical
treatment: the preferred focus is the use of conventional
compounds.
A substantial variety of blockers inhibiting CP-AMPARs
is currently available. They can be divided in two principal
groups of: (i) organic toxins (philanthotoxin, joro spider toxin,
argiotoxin; Blaschke et al., 1993; Herlitze et al., 1993; Gu et al.,
1996) and (ii) dicationic compounds (IEM-1460, IEM-1754,
IEM-1925; Magazanik et al., 1997; Tikhonov et al., 2000; Zaitsev
et al., 2011). Studies of the effects of organic toxins on pain
showed the attenuated development of injury-evoked allodynia
when organic toxins (joro spider toxin, philanthotoxin) were
used as a pre-treatment (Sorkin et al., 1999, 2001; Pogatzki
et al., 2003). However, pain maintenance was unchanged
when they were administered as a post-treatment, even in
comparatively high doses (Jones and Sorkin, 2004). Strikingly,
the effects of dicationic compounds on pain management have
not been investigated. In the meantime, they are of special
interest since the revealed capability to inhibit CP-AMPARs
in the voltage- and the use-dependent manner (Magazanik
et al., 1997; Tikhonov et al., 2000; Tikhonova et al., 2008;
Zaitsev et al., 2011). The use-dependent inhibition might be
the key to impede the development of adverse effects because it
‘‘switches off’’ only functionally active (upregulated) receptors
rather than blocking the entire receptor pool. Cumulatively,
the effectiveness of use-dependent inhibition correlates with
the number of activated receptors/open channels (Zaitsev
et al., 2011). Previously, we have demonstrated the increased
number of functional CP-AMPARs in DH interneurons in
persistent pain conditions: this resulted from promoted insertion
of GluR1-containing AMPARs into extrasynaptic plasma
membrane (Kopach et al., 2011, 2013) and internalization of
GluR2-containing AMPARs from synapses between primary
afferents and DH interneurons (Park et al., 2009). In addition,
we have shown the capability of dicationic compound IEM-1460
to reverse the inflammatory-induced changes in the AMPAR-
mediated currents in DH interneurons (Kopach et al., 2011).
Despite the evidenced effects of dicationic compounds at the
cellular level, their effects on chronic pain in vivo have not been
tested yet.
MATERIALS AND METHODS
Animal Care
Animals used in the study were 3–5 weeks-old male Wistar rats.
All animal procedures were approved by the local Animal Ethics
Committee (Bogomoletz Institute of Physiology, Kyiv, Ukraine)
and were performed in accordance with ethical guidelines of the
IASP and the European Commission Directive (86/609/EEC).
Great care was taken to avoid or minimize any discomfort of the
animals with all efforts made to reduce the number of animals
used.
Intrathecal Catheter Implantation
For local delivery of dicationic compounds into the spinal
cord we used intrathecal catheter implantation according to
a method previously described for rats (Kopach et al., 2013).
Briefly, a rat was anesthetized with an intraperitoneal (i.p.)
injection of a mixture of ketamine (Farmak, Ukraine) and
xylazine (Farmak, Ukraine) in the doses of 70 mg kg−1 and
25 mg kg−1, respectively. Anesthetized rat was placed in a
stereotaxic frame with the head securely fixed between ear bars.
One incision was made below the nape 1 cm caudal to the neck.
The external occipital crest muscles were retracted with extra
care to expose the atlanto-occipital membrane. A polyethylene
tube (PE-10) was inserted into the subarachnoid space at the
rostral level of the spinal cord region around Th10-L2 spinal
segments through an incision at the atlanto-occipital membrane
(Figure 1A). Extra care was taken to avoid any damage of
the spinal cord. The incision was closed with silk sutures
and treated with Betadine (Gedeon Richter Ltd, Budapest,
Hungary). Animals received postoperatively bicillin (0.6 million
U kg−1, i.p., Farmak, Ukraine) and dexamethazon (60 mg kg−1,
i.p., Farmak, Ukraine) and were maintained in a warmed
area until full recovery from anesthesia. Animals were housed
postoperatively in a temperature-controlled environment with
food and water ad libitum. They were recovered postoperatively
for several days before being used in experiments (typically 5 days
or until the complete healing of surgical incision if needed).
Animals showing any neurological deficits were discarded. The
position of the catheter has been confirmed in each animal after
termination of an experiment.
Induction of Peripheral Inflammation
To produce unilateral peripheral inflammation and nociceptive
hypersensitivity, 50–100 µl of complete Freund’s adjuvant (CFA,
Mycobacterium tuberculosis) suspended in an oil-saline (1:1)
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FIGURE 1 | The concentration-dependent alleviation of thermal nociceptive hypersensitivity by the dicationic compound IEM-1460. (A) Photograph of
a rat with implanted catheter into spinal cord column. (B) Fluorescent images of different areas of freshly dissected spinal cord after i.t. injection of morphological dye
Alexa-594 (100 µM, 10 µl) into the lumbar spinal cord showing the fluorescence in the dorsal spinal cord (lumbar segments), but not in the ventral spinal cord with
notably dim fluorescent signal along the attached roots. (C) Hargreaves pain behavioral test in different groups of animals demonstrates that post-treatment of
complete Freund’s adjuvant (CFA)-induced inflammatory pain with the dicationic compound IEM-1460 alleviates thermal pain hypersensitivity in rats. Data are
expressed as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 for 3 µM of IEM-1460 vs. the correspondent time-point in the CFA-inflamed group. #p < 0.05,
##p < 0.01 for 30 µM of IEM-1460 vs. the correspondent time-point in the CFA-inflamed group. One-way analysis of variance (ANOVA) and Bonferroni post hoc test.
(D) The paw withdrawal latencies in different groups of animals treated with IEM-1460 were normalized to the correspondent value prior to starting the treatment
(2 h) to demonstrate the time-dependence of pain relief on the compound concentration. (E) The concentration-inhibition curves of IEM-1460-induced inhibition of
inflammatory pain for the acute and the long-lasting responses.
emulsion was injected subcutaneously into the plantar side of one
hind paw of the rats. Saline (0.9%; 100 µl) injection was used as a
control.
Intrathecal Drug Administration
Dicationic compounds were delivered intrathecally (i.t.) into the
dorsal spinal cord as confirmed with the Alexa-596-mediated
fluorescence detected preferentially at the dorsal lumbar spinal
cord (L1–L3 segments), but not at the ventral lumbar spinal
cord or along the attached roots (Figure 1B). Different groups
of animals (non-inflamed, CFA-inflamed) received a treatment
with saline (control), IEM-1460 or IEM-1925 at indicated
concentrations. Injection of a drug (10 µl, diluted in saline)
was followed by administration of saline (10 µl) to flush the
catheter. Dicationic compounds were used as a post-treatment
of peripheral hypersensitivity developed after the induction
of peripheral inflammation. After validation that peripheral
nociceptive hypersensitivity had profoundly developed following
an intraplantar injection of CFA, animals were given a single drug
injection (at 2 h post-CFA) or two drug injections (at 2 h and at
5 h after injection of CFA). Timing of starting a treatment was
based on our earlier studies of the time-dependent inflammatory
changes in the DHGluR2 phosphorylation (Park et al., 2009) and
the AMPAR-mediated currents in lamina II DH interneurons
(Kopach et al., 2012) in the samemodel of long-lasting peripheral
inflammation in rats.
For assessment of possible side effects of the compounds
animals were thoroughly observed for the signs of motor
deficit, impaired/irregular movement, stress and anxiety over
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the entire period of testing an animal. In addition, groups of
animals, which received dicationic compounds alone (without
induction of peripheral inflammation), were tested for their
behavioral responses to peripheral stimulation of different
modality (thermal, mechanical) and for sings of possible
locomotive deficit and/or the anxiety-like behavior following
treatment.
Behavioral Testing
Behavioral tests were performed in a quiet room, by the
experimenter evaluating the animal’s behavior in a blind manner
(the experimenter did not know if the animals were treated with
saline or drug).
Hargreaves Plantar Test
The paw withdrawal responses to thermal stimuli were measured
using the Hargreaves technique as described in details previously
(Park et al., 2009; Kopach et al., 2013). Briefly, after an animal
was habituated to a Plexiglas chamber located above a light box,
a radiant heat was applied to the middle of the plantar surface
of one hind paw. The intensity of thermal stimulus applied to
the plantar skin was adjusted to temperature of ∼46◦C (30 s
cut off). The light beam was automatically turned off when the
animal lifted its paw. The time between starting the stimulus
and lifting the paw was defined as the paw withdrawal latency.
The trial was repeated 3–5 times for each paw with intervals
betweenmeasurements for at least 3–4min. For representation of
the time-dependent changes produced by dicationic compounds
in various concentrations (Figure 1D), the paw withdrawal
responses in different experimental groups were normalized to
the correspondent value measured prior to starting the treatment
(2 h post-CFA) as indicated.
Method of von Frey’s Monofilaments
The paw withdrawal responses to the repeated mechanical
stimuli were measured using the method of von Frey
monofilaments as described previously (Park et al., 2009;
Kopach et al., 2013). Briefly, after an animal was habituated
to a Plexiglas chamber on an elevated mesh screen (at least
10–15 min prior to testing), the von Frey monofilaments of
different intensity of stimulus (Bioseb) were applied to each
hind paw. The monofilaments were chosen according to our
previous studies of the development and maintenance of
the mechanical hypersensitivity and allodynia in the CFA-
induced model of peripheral inflammation in rats (Kopach
et al., 2012, 2013). The trial was repeated 10 times for each
hind paw with an interval between filament applications for
at least 1 min. The percentage of responses was calculated
for each trial and was defined as the paw withdrawal
frequency.
Open-Field Test
For assessment of changes in locomotion and general activity
of animals in the persistent pain conditions or during an
experimental treatment, the open-field test was performed.
The open-field test (open-field arena) represents a robust
assay for an integrative analysis of animal activity (such as
exploratory behavior, sedation, stress/anxiety etc.) as described
in detail elsewhere (Bellavance and Beitz, 1996; Bailey and
Crawley, 2009). We assessed the animal locomotion and the
anxiety-like behavior (which is commonly used to represent
side effects) by testing animals in an open-field arena during
the defined period of time. For this, a rat was placed in the
open-field arena representing a 75 cm × 75 cm × 40 cm
wooden box with a digital camera (Logitech C270) attached
above a center of the arena to record relocations of animal
through the box. Tested animal was allowed to move freely
within box during 5 min, often used session duration to
sufficiently capture the critical components of animal’ behavior.
The total distance traveled by an animal horizontally was
analyzed offline and defined as the index of locomotion.
The anxiety-like behavior (Buccafusco, 2009) was assessed by
the animal movement with regard to the time spent in the
box corners, traveling close to the walls (indicating increased
anxiety) and crossing the central area (representing the innate
behavior of animals to explore novel environments). Testing
was typically performed at the same period of time to minimize
influencing of animal behavior with a daily activity of laboratory
animals.
Statistical Analysis
All data are presented as mean ± standard error of the mean
(SEM) with n referring to the number of animals tested. The
statistical difference between experimental groups was analyzed
by one-way or two-way analysis of variance (ANOVA) followed
by Bonferroni post hoc test where appropriate. A p value of less
than 0.05 was considered as statistically significant.
Experimental Drugs
CFA was purchased from Sigma-Aldrich Company Ltd.
(St. Louis, MO, USA and Dorset, UK). 1-trimethylammonio-5-
1-adamantane-methyl-ammoniopentane dibromide (IEM-1460)
was purchased from Tocris Bioscience (Ellisville, MO, USA).N1-
(1-phenylcyclohexyl)pentane-1,5-diaminium bromide (IEM-
1925) was provided by Prof. L. Magazanik and Dr. D. Tikhonov
(I.M. Sechenov Institute of Evolutionary Physiology and
Biochemistry RAS, Saint-Petersburg, Russia) and purchased also
from Insight Biotechnology (Wembley Middlesex, UK).
RESULTS
For assessment of a capability of dicationic compounds to
alleviate nociceptive hypersensitivity during persistent pain
conditions, two different compounds, IEM-1460 and IEM-1925,
those high-potent ability to inhibit CP-AMPARs in the use-
dependent manner has been proved in vitro and in situ
(Magazanik et al., 1997; Buldakova et al., 1999; Tikhonov
et al., 2000; Tikhonova et al., 2008; Zaitsev et al., 2011), were
tested in vivo in a model of the CFA-induced long-lasting
peripheral inflammation. Dicationic compounds were used as a
post-treatment of inflammatory pain that had developed after
induction of peripheral inflammation. The compounds were
administered i.t. at different concentrations to figure out their
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efficacy in alleviating the inflammatory pain hypersensitivity of
different modalities (thermal, mechanical) and in recovering the
locomotive deficit and depressed activity of inflamed animals.
Dicationic Compound IEM-1460 Efficiently
Alleviates Inflammatory Hyperalgesia
First we tested whether the dicationic compound IEM-1460
could produce antinociceptive effect on thermal pain
hypersensitivity that had developed after the induction of
CFA-induced unilateral inflammation in rats. Consistent with
our previous studies and those of others (Park et al., 2008,
2009; Kopach et al., 2012, 2013), intraplantar injection of CFA
into a rat hind paw produced a robust thermal hypersensitivity
on the ipsilateral (but not on the contralateral) side, which
developed rapidly (30 min to 1 h after injection), maintained
at a peak level for next hours and persisted over several weeks
(n = 20, p < 0.01), representing the period of CFA-induced
inflammatory pain maintenance (Figures 1C,D). IEM-1460
given i.t. as a post-treatment of CFA-induced inflammatory
pain markedly alleviated the inflammatory-induced thermal
hypersensitivity. Relief in inflammatory pain appeared shortly
after the compound administration (within 1–2 h after i.t.
IEM-1460 application that was 3–4 h post-CFA) and was
manifested as the increase in the paw withdrawal latency of
inflamed paw, reduced after the induction of inflammation.
This increase produced by IEM-1460 reflects the reduction
in thermal hyperalgesia; it has been observed within hours
after starting the treatment (acute effect) and lasted for at least
seven consecutive days after treatment, reflecting the long-
lasting antinociceptive effects of the compound (Figures 1C,D).
The relief in pain was concentration-dependent, displaying
the profound antihyperalgesic effect produced by IEM-1460 at
the micromolar concentration range, 3–300 µM, for both acute
and chronic responses (Figure 1E). The fastest outcome for
pain relief following IEM administration was observed when
IEM-1460 was administered at the concentration of 3 µM
(Figure 1D), a concentration very close to the estimated IC50
for blocking specifically CP-AMPARs (Buldakova et al., 1999).
In particular, the paw withdrawal latency in inflamed-animals,
which received 3 µM of IEM-1460 (n = 7 per group), has been
recovered by approximately 60% of its pre-inflammatory level
after 2 h of starting the treatment. After 5 days of treatment
with 3 µM IEM-1460, the thermal pain sensitivity of inflamed
paw was comparable with those of non-inflamed animals
(saline-treated, n = 6 per group, p > 0.05; Figures 1C–E).
Lowering concentration of IEM-1460 to 1 µMor on the contrary
increasing it to 1 mM (the estimated IC50 value for blocking
GluR2-containing Ca2+-impermeable AMPARs; Buldakova
et al., 1999) resulted in a short-term reduction in thermal
hyperalgesia, observed as a peak increase of the paw withdrawal
latency (or a plateau of 1-2 h duration), which steadily declined
returning back to the CFA-inflamed level (Figures 1C,D).
The capability of dicationic compound IEM-1460 to alleviate
persistent inflammatory pain in vivo was next tested for
the inflammatory-induced mechanical hypersensitivity using
the method of von Frey monofilaments. Consistent with
previous results (Park et al., 2008, 2009; Kopach et al., 2012,
2013), injection of CFA produced a profound allodynia and
the robust mechanical hypersensitivity in response to the von
Frey monofilaments of different intensity (Figure 2A) that
revealed on the ipsilateral (but not on the contralateral) side.
IEM-1460 alleviated the CFA-induced allodynia and mechanical
hypersensitivity when applied at a micromole concentration
range according with the sufficiently alleviated chronic
thermal hypersensitivity, demonstrated above. IEM-1460 at
the concentration 30 µM or 300 µM substantially reduced the
inflammatory-induced mechanical hypersensitivity in response
to the 2 g and 4 g von Frey monofilaments, which produced
around 50% of responses in inflamed rats (the mechanical
pain threshold), after 2–3 days of treatment (n = 5 per group;
Figure 2B). After 3 days of treatment, mechanical sensitivity
of inflamed paw was indistinguishable from those of non-
inflamed animals (p > 0.05; Figures 2B,C), indicating that
IEM-1460 markedly shortened mechanical pain maintenance.
Together, these data demonstrate that dicationic compound
IEM-1460 efficiently alleviates inflammatory hyperalgesia of
different modalities (thermal, mechanical) and shortens chronic
pain maintenance acting within the micromole concentration
range.
The Recovered Locomotion and Diverted
Anxiety-Like Behavior of Inflamed Animals
After Treatment with IEM-1460
The open-field test is based on the innate behavior of rodents
to explore novel area/surroundings, allowing monitoring and
assessment of locomotion, exploratory behavior and general
activity of tested animals for integrative analysis of sersorimotor
function upon a treatment (Bellavance and Beitz, 1996; Bailey
and Crawley, 2009). For assessment of the inflammatory-
induced locomotive deficit and the impaired activity of animals
in persistent pain conditions, we tested animals prior to the
induction of peripheral inflammation and at different time-
points following the developed inflammatory pain to compare
animal locomotion and explorative behavior between conditions.
The robust reduction in animal locomotion together with the
profoundly suppressed general activity of animals have been seen
shortly after the induction of inflammation (within first few
hours), which declined further and maintained at a stably low
level for a long period of time (Figures 3A,B; for at least few
weeks). For instance, the total distance traveled by an inflamed
animal on day 1 after CFA injection was reduced up to ninefold
as compared to the distance traveled by the animal prior to
the inflammation (n = 28 per group, p < 0.001; Figure 3B)
or to that one in the saline-treated group (n = 11 per group,
p < 0.001; Figure 3B). Typically, the animals with inflamed paw
spent a time by predominantly sitting in the arena corners with
no attempts to explore surroundings over the entire recording
session, displaying the anxiety-like behavior during the persistent
pain syndrome (Figures 3A,B).
Further studying a capability of dicationic compound
IEM-1460 to alleviate persistent inflammatory pain, we have
tested whether the pain relief produced by IEM-1460 would
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FIGURE 2 | Analgesic effect of IEM-1460 on the inflammatory-induced mechanical hypersensitivity. (A) von Frey behavioral test demonstrates tactile
allodynia in the CFA-inflamed rats in response to von Frey monofilaments of different stimulus intensity. (B) Treatment with IEM-1460 recovered the paw withdrawal
frequency in response to the 2 g (left graph) and 4 g (right graph) von Frey monofilaments. Results are presented as mean ± SEM. ∗∗p < 0.01, ∗∗∗p < 0.001 for
30 µM of IEM-1460 vs. the correspondent time-point in the CFA-inflamed group. #p < 0.05, ##p < 0.01 for 300 µM of IEM-1460 vs. the correspondent time-point in
the CFA-inflamed group. One-way ANOVA and Bonferroni post hoc test. (C) Post-treatment with IEM-1460 recovered tactile allodynia in the CFA-inflamed rats after
3 days of treatment.
accompany by alleviation in the locomotive deficit developed
in inflamed animals. We first verified that the impairments
had developed after the induction of inflammation and then
tested the animals following treatment once a day until the
parameters reached a complete recovery (Figure 3C). Treatment
with IEM-1460 improved the locomotion of inflamed animals,
revealing the increase in the total distance traveled by an
animal with inflamed paw (Figures 3C,D). This improvement
has been observed even after 1 day of treatment; it further
progressed following next days, showing the restored ability of
inflamed animals to travel as much as prior to the induction of
inflammation after 3 days of treatment with IEM-1460 at either
tested concentration (n = 5–6 per group; Figure 3D). This is
consistent with the time-course of recovery in the CFA-induced
mechanical hypersensitivity by IEM-1460, demonstrated above.
The alleviated locomotive deficit was accompanied by facilitated
exploratory behavior of inflamed animals that was revealed as
their increased crossing of the central area of arena (Figure 3E).
Such behavior indicates the recovered general activity of
inflamed animals after treatment with IEM-1460 along with
the diverted stress and anxiety, which had been developed in
persistent pain conditions.
Assessment of Possible Side Effects
Developed by Treatment with IEM-1460
For assessment of possible side effects developed upon inhibition
of spinal CP-AMPARs with dicationic compound IEM-1460,
animals were tested for their responses to thermal and
mechanical peripheral stimulations as well as their locomotive
and the anxiety-like behavior before and after the treatment with
IEM-1460 at different concentrations.
To thoroughly evaluate if an acute and/or a delayed adverse
effect might develop upon a treatment, we tested the basal
thermal nociceptive sensitivity by measuring the paw withdrawal
latency before and every next hour (a 6 h-duration) after
starting the treatment and then once a day over a week
afterwards. Groups of animals, which received IEM-1460 at
different concentrations, did not differ in their withdrawal
latency at any time-point tested (within hours or days after
treatment) as compared to the value prior to starting the
treatment or that value in control littermates (saline; p > 0.05;
Figure 4A). Similar to this, groups of animals did not also
differ with regard to their basal mechanical sensitivity following
treatment with IEM-1460 (n = 5–6 per group, p > 0.05;
Figure 4B).
Further, no significant changes were observed in the animal
locomotion (n = 5, p > 0.05; Figure 4C) after inhibition of
spinal CP-AMPARs with 3 µM IEM-1460, which produced the
fastest outcome for modulating pain in vivo and also represents
the estimated IC50 for blocking CP-AMPARs (Buldakova
et al., 1999). Finally, IEM-1460 (3 µM) did not give rise
to the anxiety-like behavior, the commonly used readout of
side effects, since none of three parameters tested for the
signs of increased anxiety were significantly different between
the IEM-1460-treated animals and the control (saline-treated)
group (n = 5 per group for 3 µM IEM-1460, n = 11 per
group for saline; p > 0.05; Figure 4D). We have analyzed:
(i) the total time of running along the walls; (ii) time spent
within the central area of arena; and (iii) crossing the arena
center (Figure 4D). Notably, animals of both tested groups
demonstrated promoted attempts to explore the open-field arena
over the entire period of testing (for several days) by crossing
the central area rather than running along the walls when
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FIGURE 3 | The IEM-1460-induced relief in locomotive deficit and the anxiety-like behavior of inflamed animals. (A) The open-field test snapshots
demonstrate the severe locomotive deficit in rats with developed peripheral pain syndrome. Sketches of the animal movements taken from the same animal before
and at different time-points after induction of inflammation indicating the total distance traveled by an animal for 5 min of recording. (B) Summary of the total distance
traveled (a 5 min duration) by the saline-treated and the CFA-inflamed animals over the time. Data are expressed as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01,
∗∗∗p < 0.001 vs. the correspondent time-point in saline. One-way ANOVA and Bonferroni post hoc test. (C–E) Treatment with IEM-1460 recovered the
inflammatory-induced locomotive deficit (D) and the anxiety-like behavior (E) as seen from the representing open-filed recordings taken from the same animal before
and after the induction of peripheral inflammation followed by IEM-1460 treatment (C). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the indicated bar. One-way ANOVA
and Bonferroni post hoc test.
compared both parameters at different time-points to those
ones taken from starting testing (Figure 4D). Together these
data demonstrate that treatment with IEM-1460 produces no
adverse effects on basal peripheral sensitivity (neither thermal
nor mechanical), the locomotive behavior and on none of
tested parameters representing the anxiety-like behavior of tested
animals.
Antinociceptive Effects of Dicationic
Compound IEM-1925 on Inflammatory
Hypersensitivity and Locomotive Deficit
Despite the proven high-potent capability of dicationic
compound IEM-1925 to inhibit CP-AMPARs in the
activity-dependent manner (Tikhonov et al., 2000; Zaitsev
et al., 2011), the effects of such inhibition in vivo have not been
tested yet. Here we have studied a capability of the compound
to alleviate thermal and mechanical hypersensitivities and to
restore the locomotive deficit and suppressed activity of animals
with persistent peripheral inflammation when inhibit spinal
CP-AMPARs with dicationic compound IEM-1925 in vivo. As
in the case of IEM-1460, IEM-1925 markedly alleviated the
inflammatory-induced thermal hypersensitivity when used as a
post-treatment of CFA-induced inflammatory pain (Figure 5A).
The effect of IEM-1925 was dose-dependent, displaying a
profound relief in thermal hyperalgesia (either acute or chronic
responses) when drug was applied at a micromole concentration
range, 5–300 µM (Figure 5B). I.t. administration of IEM-1925
(5–300 µM) resulted in attenuated thermal hypersensitivity,
which lasted over the entire period of testing (at least 7 days;
n = 5 per group for 5 µM IEM-1925; n = 15 per group for
20 µM IEM-1925; n = 9 per group for 300 µM IEM-1925).
Relief in pain produced by IEM-1925 appeared faster than for
IEM-1460 used at the similar concentration range. In particular,
thermal pain sensitivity of inflamed paw was indistinguishable
from that in non-inflamed animals after 3 days of treatment
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FIGURE 4 | Dicationic compound IEM-1460 does not give rise to detectable side effects. (A) The Hargreaves test demonstrates that treatment with
IEM-1460 at different concentrations produces neither acute nor delayed changes in thermal peripheral sensitivity. Data are expressed as the mean paw withdrawal
latencies normalized to the correspondent time-point in the saline-treated group. (B) The von Frey behavioral test shows no changes in the mechanical peripheral
sensitivity in response to the 2 g (left graph) and 4 g (right graph) von Frey monofilaments in rats treated with IEM-1460. Results are presented as mean ± SEM.
(C,D) The open-field test demonstrates no significant changes in animal locomotion (C) and the anxiety-like behavior (D) after treatment with 3 µM IEM-1460.
The anxiety-like behavior was assessed by changes in the time of running along the walls (left graph in D), the time spent within the central area of arena (middle bars
in D) and crossing by animal the arena center (right bars in D); results are presented as mean values normalized to the correspondent time-point prior to the
treatment (Pre).
with IEM-1925 (p > 0.05; Figure 5A), indicating the profound
shortening of the inflammatory pain maintenance by IEM-1925
(Figures 5A,B). Similar to IEM-1460, lowering concentration
of IEM-1925 to 1 µM or opposite increasing it to 1 mM (the
highest drug concentration tested) produced the reduction of
thermal hypersensitivity for a short period of time, which lasted
within hours (for 1 µM IEM-1925) or for a few days only (for
1 mM IEM-1925) after treatment with following decline of the
paw withdrawal latency back to the CFA-inflamed level (n = 6
per both groups; Figure 5A).
IEM-1925 also alleviated the CFA-induced mechanical
hypersensitivity and allodynia in inflamed rats. As in the
case of thermal hyperalgesia, IEM-1925 alleviated mechanical
hypersensitivity faster than IEM-1460. The CFA-induced
mechanical hypersensitivity in response to either 2 g or the
4 g von Frey filaments was substantially alleviated even after
2 days of treatment with 20 µM IEM-1925 (n = 5 per group;
Figures 5C,D); after 3 days of treatment the withdrawal
frequency of inflamed paw was comparable to its basal
(pre-inflammatory) level (Figure 5C), indicating a complete
recovery in peripheral mechanical sensitivity by treatment
with IEM-1925.
Finally, the locomotive deficit that had developed in the
inflamed animals along to the persistent pain syndrome has been
effectively eliminated by treatment with IEM-1925. Again, the
outcome in relief produced by the treatment with IEM-1925
revealed faster than that for IEM-1460. In particular, the total
distance traveled by inflamed animals was recovered to its
pre-inflammatory level even after 1 day of treatment with
IEM-1925 at the concentration 1 µM or 5 µM, but not at a high
concentration, 1 mM (n = 5 per group; Figures 6A,B). This was
accompanied by a promoted exploratory behavior of inflamed
animals, demonstrating the increased crossing the central area
of arena (Figure 6C). The latter indicates that treatment with
IEM-1925 declines the anxiety-like behavior in CFA-inflamed
animal.
Dicationic Compound IEM-1925 Affects
None of Tested Parameters for Possible
Side Effects
For assessment of possible side effects developed upon inhibition
of spinal CP-AMPARs with dicationic compound IEM-1925,
we first tested whether IEM-1925 could influence peripheral
sensitivity of animals to different stimulus modalities (thermal,
mechanical). No detectable changes in thermal nociceptive
sensitivity were found in rats following i.t. administration
of IEM-1925 within hours (acute effect) and during next
several days after treatment (delayed effect) as compared to
their sensitivity prior to starting the treatment or to this
sensitivity in the control (saline-treated) group (p > 0.05;
Figure 7A). Neither of tested concentration of the compound
affected the animals’ thermal nociceptive sensitivity over
the time. Treatment with IEM-1925 did not also change
the basal mechanical sensitivity of animals in response
to the 2 g or 4 g von Frey filaments following next
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FIGURE 5 | Antinociception produced by dicationic compound IEM-1925 on the inflammatory-induced thermal and mechanical hypersensitivities.
(A) The Hargreaves pain behavioral test demonstrates the reduced thermal inflammatory hypersensitivity following treatment with IEM-1925 at different
concentrations. Data are expressed as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 for 5 µM of IEM-1925 vs. the correspondent time-point in the
CFA-inflamed group. #p < 0.05, ##p < 0.01 for 1 µM of IEM-1925 vs. the correspondent time-point in the CFA-inflamed group. §p < 0.05, §§p < 0.01, §§§p < 0.001
for 20 µM of IEM-1925 vs. the correspondent time-point in the CFA-inflamed group. One-way ANOVA and Bonferroni post hoc test. (B) The concentration-inhibition
curves of the IEM-1925-mediated inhibition of the thermal inflammatory hypersensitivity for the acute and long-lasting inhibitory effects. (C,D) The von Frey behavioral
test demonstrates the alleviated mechanical hypersensitivity by IEM-1925 (20 µM) in response to the 2 g (left graph) and 4 g (right graph) von Frey filaments (C) and
the IEM-1925-mediated relief in the inflammatory-induced tactile allodynia in CFA-inflamed animals on day 2 after treatment (D). Results are presented as
mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 for 20 µM of IEM-1925 vs. the correspondent time-point in the CFA-inflamed group. One-way ANOVA and
Bonferroni post hoc test.
several days after treatment (n = 6 per group, p > 0.05;
Figure 7B).
Consistent with these results and those reported above for
dicationic compound IEM-1460, IEM-1925 did not change the
animal locomotion as determined by the unaltered total distance
traveled by an animal following treatment with 5 µM IEM-1925
(n = 5 per group, p> 0.05; Figure 7C). Treatment with IEM-1925
did not also give rise to the anxiety-like behavior, since the
time of running along the walls remained indistinguishable
from that in the saline-treated animals (Figure 7D, left
graph) and each of tested parameters reflecting the animal
exploratory behavior did not decline over the time of treatment
with IEM-1925 (Figure 7D, right bars). Thus, IEM-1925 did
not give rise to detectable acute and/or delayed side effects
in rats.
DISCUSSION
Cumulative evidence indicates the key role of AMPARs in
central sensitization of the DH, a specific form of plasticity
in the spinal cord underlying the central mechanism
by which peripheral pain develops and is maintained
(Woolf and Salter, 2000; Ji et al., 2003). Inhibition of spinal
AMPARs with conventional antagonists (NBQX, CNQX,
GYKI 52466, CFM-2) reversed mechanical allodynia and
both thermal and mechanical hypersensitivities during the
development and maintenance of pain of various origins
(Sorkin et al., 2001; Nozaki-Taguchi and Yaksh, 2002; Jones
and Sorkin, 2004; Park et al., 2008). However, inhibition
of AMPARs with competitive antagonists affected the basal
peripheral sensitivity and caused sedation (Hao and Xu,
1996; Park et al., 2008) that makes this approach impractical.
Studies of the molecular mechanisms of persistent pain
maintenance demonstrated the upregulation of CP-AMPARs
either at the synapses (Hartmann et al., 2004; Vikman et al.,
2008; Park et al., 2009) or at the extrasynaptic membranes
of DH interneurons (Park et al., 2009; Kopach et al., 2011,
2013), both of those are causally linked to the maintenance
of persistent inflammatory pain, since prevention of the
CP-AMPAR upregulation in DH interneurons through
targeted genetic interfering with the receptor trafficking
machinery has effectively alleviated persistent inflammatory
pain at the periphery (Park et al., 2009; Kopach et al., 2013).
However, usage of genetic approaches remains restricted in
treatment, with preferred focus on commercially available
drugs.
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FIGURE 6 | The IEM-1925-induced relief in locomotive deficit and the anxiety-like behavior in CFA-inflamed animals. (A) The representative sketches of
the open-field test, taken from the same animal, show the distance traveled by the animal before and after the induction of peripheral inflammation, followed by
treatment with 5 µM IEM-1925. (B–C) Summary of the restored both locomotive deficit (B) and suppressed activity of the animals with inflamed paw (C) after
treatment with IEM-1925. Data are expressed as mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. the indicated bar (the correspondent time-point in
CFA-inflamed group without treatment). One-way ANOVA and Bonferroni post hoc test.
Among two principal groups of the selective antagonists of
CP-AMPARs, the group of organic toxins has been extensively
explored for their effectiveness in managing pain in various
pain models (Sorkin et al., 1999, 2001; Pogatzki et al., 2003;
Jones and Sorkin, 2004), whereas the effects of dicationic
compounds have not been studied in vivo at all, leaving
the whole class of blockers open for further considerations.
In the meantime, a capability of dicationic compounds
(IEM-1460, IEM-1754, IEM-1925) to block CP-AMPARs
in the activity-dependent manner (Magazanik et al., 1997;
Tikhonov et al., 2000; Zaitsev et al., 2011) may provide their
potential effectiveness in pain relief. As the open-channel
antagonists acting in the use-dependent manner, dicationic
compounds inhibit CP-AMPARs only if receptor is open
that the effectiveness of blockage correlates with the number
of open channels (Zaitsev et al., 2011). Therefore, we have
tested two dicationic compounds, IEM-1460 and IEM-1925,
which capability to inhibit neuronal CP-AMPARs in the
use-dependent manner had been proved already (Magazanik
et al., 1997; Tikhonov et al., 2000; Tikhonova et al., 2008;
Zaitsev et al., 2011) to figure out their effectiveness in
managing persistent inflammatory pain in vivo. Dicationic
compounds were applied i.t. as a post-treatment of persistent
inflammatory pain that had developed in the CFA-induced
model of long-lasting peripheral inflammation. Either IEM-1460
or IEM-1925 produced profound alleviation of inflammatory
hypersensitivity. Firstly, relief in pain appeared shortly after
compound administration (within hours). Secondly, the
reduction in inflammatory hypersensitivity lasted for a long
period of time, resulting thirdly, in a marked shortening of the
period of pain maintenance after treatment with dicationic
compounds. The effects obtained with using dicationic
compounds here are consistent with those demonstrated
previously when we prevented the upregulation of CP-AMPARs
in DH interneurons by utilizing a gene-targeted strategy
(Park et al., 2009; Kopach et al., 2013). However, the effects
of dicationic compounds on inflammatory pain maintenance
contrast with those reported for organic toxins (joro spider
toxin, philantotoxin), which attenuated the development of
thermal injury-evoked mechanical allodynia (Sorkin et al.,
1999, 2001), carrageenan-induced hyperalgesia (Sorkin et al.,
2001) and mechanical allodynia in the postincision pain
model (Pogatzki et al., 2003), but failed to alleviate the
pain maintenance (Sorkin et al., 2001; Jones and Sorkin,
2004). Such discrepancy very likely relates to different
pain models and reflects also a different involvement of
CP-AMPARs in mechanisms underlying development and
maintenance of pain of various origins. Consistent with this
assumption, the acute effects of dicationic compounds on
thermal hypersensitivity were similar to those produced by
organic toxins (Sorkin et al., 1999, 2001; Pogatzki et al.,
2003).
Dicationic compounds alleviated inflammatory pain in
the concentration-dependent manner, displaying the fastest
and maximal pain relief when IEM-1460 or IEM-1925 was
used at the concentration very close to the value estimated
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FIGURE 7 | IEM-1925 does not give rise to detectable side effects. (A) The Hargreaves test demonstrates neither acute nor delayed changes of thermal
peripheral sensitivity in rats after treatment with dicationic compound IEM-1925 at different concentrations. Data are expressed as the mean paw withdrawal
latencies normalized to the correspondent time-point in the saline-treated group. (B) The von Frey behavioral test shows no changes in the mechanical peripheral
sensitivity in response to the 2 g (left graph) and 4 g (right graph) von Frey monofilaments in rats treated with 20 µM IEM-1925. Results are presented as
mean ± SEM. (C,D) The open-field test shows no changes in animal locomotion (C) and no rise in the anxiety-like behavior (D) following treatment with 5 µM
IEM-1925. Assessment of the anxiety-like behavior was similar as in Figure 4D; results are presented as mean values normalized to the correspondent time-point
prior to the treatment (Pre) for all parameters tested.
as IC50 for blocking CP-AMPARs (Buldakova et al.,
1999). Either compound produced alleviation in persistent
inflammatory pain, which: (i) appeared shortly after starting
the treatment; (ii) maintained for a long period of time (at
least 7 days); and (iii) results in a marked shortening of
inflammatory pain maintenance. However, relief in pain
produced by IEM-1925 appeared faster than by IEM-1460
(for either thermal or mechanical hypersensitivity) when
compared antinociceptive effects between the compounds.
Our in vivo observation is consistent with the reported
higher potency of IEM-1925 to inhibit CP-AMPARs in vitro
comparing to the potency of other blockers (IEM-1460,
IEM-1754) within the group of dicationic compounds
(Magazanik et al., 1997; Tikhonov et al., 2000; Zaitsev et al.,
2011). Notably, lowering concentration of drug to 1 µM or
increasing it to a milimolar range (1 mM, the concentration
representing the estimated IC50 value for blocking GluR2-
containing Ca2+-impermeable AMPARs; Buldakova et al.,
1999) resulted in the short-lasted alleviation of inflammatory
pain with a negligible effect produced by compounds on the
inflammatory pain maintenance. This is in agreement with
the causally linked upregulation of CP-AMPARs in the DH
interneurons of spinal cord to the persistent inflammatory
pain maintenance (Park et al., 2009; Kopach et al., 2011,
2013).
However, a loss of CP-AMPARs may cause adverse effects
because of the crucial role of CP-AMPARs in synaptic plasticity
that would make the prominent analgesic effects produced
by dicationic compounds impractical. Therefore, we have
thoroughly tested whether inhibition of spinal CP-AMPARs with
dicationic compounds could develop side effects by utilizing a
set of different behavioral tests to find out if any one among
a set of parameters tested is altered following treatment with
dicationic compounds. Our behavioral studies demonstrated that
neither peripheral sensitivity of different modalities (thermal,
mechanical) nor the animal locomotive behavior was changed
following treatment. Further, dicationic compounds did not give
rise to side effects developed in tested animals since none of
the commonly used parameters representing the anxiety-like
behavior had been altered (the time of running along the walls,
within the central area of arena, crossing of the arena center).
Our in vivo results are consistent with the absent changes in basal
transmission in the brain in situ when dicationic compounds
were continuously present (Zaitsev et al., 2011). Cumulatively, it
indicates that the activity-dependent inhibition of CP-AMPARs
with dicationic compounds does not lead to detectable adverse
effects.
Summarizing, dicationic compounds, the open-channel
antagonists acting in the activity-dependent manner, effectively
relieve persistent pain syndrome by alleviating a repertoire
of the inflammatory symptoms, including the peripheral
hypersensitivity of different modalities (thermal and mechanical
pain), the locomotor deficit and the suppressed activity of
injured animals in persistent inflammatory pain conditions. The
ability of dicationic compounds to provide relief in chronic
inflammatory pain represents a new reliable route for pain
management and further perspectives in a mechanism-targeted
therapy of chronic pain.
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